Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in Management of Urothelial Cancer
share announcement

Advances in Management of Urothelial Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 10 November 2024 | Viewed by 1858

Special Issue Editor

Prof. Dr. Shomik Sengupta

E-Mail Website
Guest Editor
Eastern Health Clinical School, Monash University, 5 Arnold Street, Box Hill, VIC 3128, Australia
Interests: bladder cancer; uro-oncology; clinical trial

Special Issue Information

Dear Colleagues,

Urothelial cancers, particularly arising from the bladder, represent a large healthcare burden. On the one hand, low-risk bladder cancers are common and can recur frequently, thus requiring long-term repetitive follow-up that is invasive and expensive. On the other hand, invasive bladder cancer and upper tract urothelial cancer (UTUC) are rarer but potentially lethal, hence require aggressive and morbid treatment in patients who are elderly or frail. New developments in diagnostic modalities of endoscopy, imaging, biomarkers and genomics have come about in recent years, achieving earlier diagnoses and precise classification and prognostication. In parallel, there is an increased availability of therapeutic options in terms of improved surgical tools and approaches as well as novel and targeted agents delivered systemically or endoluminally. This Special Issue will highlight many of these developments. We welcome reviews of the current status of this field, as well as original research related to the management of urothelial cancer.

Prof. Dr. Shomik Sengupta
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urothelial cancer
  • bladder cancer
  • upper tract urothelial cancer
  • diagnosis
  • treatment
  • surgery
  • chemotherapy
  • immunotherapy
  • imaging

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 373 KiB  
Article
Hyperthermic Intravesical Chemotherapy (HIVEC) Using Epirubicin in an Optimized Setting in Patients with NMIBC Recurrence after Failed BCG Therapy
by Julien Blanc, Jonathan Ruggiero, Ilaria Lucca, Nicolas Arnold, Bernhard Kiss and Beat Roth
Cancers 2024, 16(7), 1398; https://doi.org/10.3390/cancers16071398 - 02 Apr 2024
Viewed by 517
Abstract
To evaluate hyperthermic intravesical chemotherapy (HIVEC) using conductive heating and epirubicin in an optimized setting as an alternative to radical cystectomy in patients with recurrent non-muscle invasive bladder cancer (NMIBC) who have failed bacillus Calmette-Guérin (BCG) therapy. We retrospectively analyzed our prospectively recorded [...] Read more.
To evaluate hyperthermic intravesical chemotherapy (HIVEC) using conductive heating and epirubicin in an optimized setting as an alternative to radical cystectomy in patients with recurrent non-muscle invasive bladder cancer (NMIBC) who have failed bacillus Calmette-Guérin (BCG) therapy. We retrospectively analyzed our prospectively recorded database of patients who underwent HIVEC between 11/2017 and 11/2022 at two Swiss University Centers. Cox regression analysis was used for univariate/multivariate analysis, and the Kaplan–Meier method for survival analysis. Of the 39 patients with NMIBC recurrence after failed BCG therapy, 25 (64%) did not recur within the bladder after a median follow-up of 28 months. The 12- and 24-month intravesical RFS were 94.8% and 80%, respectively. Extravesical recurrence developed in 14/39 (36%) of patients. Only 7/39 (18%) patients had to undergo radical cystectomy. Seven patients (18%) progressed to metastatic disease, with five of these (71%) having previously developed extravesical disease. No adverse events > grade 2 occurred during HIVEC. Device-assisted HIVEC using epirubicin in an optimized setting achieved excellent RFS rates in this recurrent NMIBC population at highest risk for recurrence after previously failed intravesical BCG therapy. Extravesical disease during or after HIVEC, however, was frequent and associated with metastatic disease and consecutively poor outcomes. Full article
(This article belongs to the Special Issue Advances in Management of Urothelial Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 8570 KiB  
Review
Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer
by Shiv Verma, Diya Swain, Prem Prakash Kushwaha, Smit Brahmbhatt, Karishma Gupta, Debasish Sundi and Sanjay Gupta
Cancers 2024, 16(2), 246; https://doi.org/10.3390/cancers16020246 - 05 Jan 2024
Viewed by 1035
Abstract
The Melanoma Antigen Gene (MAGE) is a large family of highly conserved proteins that share a common MAGE homology domain. Interestingly, many MAGE family members exhibit restricted expression in reproductive tissues but are abnormally expressed in various human malignancies, including bladder cancer, which [...] Read more.
The Melanoma Antigen Gene (MAGE) is a large family of highly conserved proteins that share a common MAGE homology domain. Interestingly, many MAGE family members exhibit restricted expression in reproductive tissues but are abnormally expressed in various human malignancies, including bladder cancer, which is a common urinary malignancy associated with high morbidity and mortality rates. The recent literature suggests a more prominent role for MAGEA family members in driving bladder tumorigenesis. This review highlights the role of MAGEA proteins, the potential for them to serve as diagnostic or prognostic biomarker(s), and as therapeutic targets for bladder cancer. Full article
(This article belongs to the Special Issue Advances in Management of Urothelial Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop